GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Cyclically Adjusted PB Ratio

Alkermes (Alkermes) Cyclically Adjusted PB Ratio : 2.80 (As of Apr. 27, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Alkermes Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Alkermes's current share price is $24.68. Alkermes's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $8.82. Alkermes's Cyclically Adjusted PB Ratio for today is 2.80.

The historical rank and industry rank for Alkermes's Cyclically Adjusted PB Ratio or its related term are showing as below:

ALKS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.65   Med: 4.52   Max: 15.13
Current: 2.8

During the past years, Alkermes's highest Cyclically Adjusted PB Ratio was 15.13. The lowest was 1.65. And the median was 4.52.

ALKS's Cyclically Adjusted PB Ratio is ranked worse than
66.77% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs ALKS: 2.80

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alkermes's adjusted book value per share data for the three months ended in Dec. 2023 was $7.203. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.82 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alkermes Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alkermes's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Cyclically Adjusted PB Ratio Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 2.45 2.68 2.82 3.15

Alkermes Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.82 3.00 3.29 2.92 3.15

Competitive Comparison of Alkermes's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Cyclically Adjusted PB Ratio falls into.



Alkermes Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alkermes's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=24.68/8.82
=2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Alkermes's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=7.203/120.1096*120.1096
=7.203

Current CPI (Dec. 2023) = 120.1096.

Alkermes Quarterly Data

Book Value per Share CPI Adj_Book
201403 9.273 100.573 11.074
201406 9.280 100.773 11.061
201409 9.129 100.474 10.913
201412 9.468 99.576 11.420
201503 9.566 99.975 11.493
201506 9.370 100.573 11.190
201509 9.121 100.274 10.925
201512 8.721 99.676 10.509
201603 8.373 99.676 10.089
201606 8.208 101.072 9.754
201609 7.969 100.274 9.545
201612 7.935 99.676 9.562
201703 7.946 100.374 9.508
201706 7.824 100.673 9.335
201709 7.722 100.474 9.231
201712 7.810 100.075 9.374
201803 7.457 100.573 8.906
201806 7.457 101.072 8.862
201809 7.407 101.371 8.776
201812 7.520 100.773 8.963
201903 7.025 101.670 8.299
201906 6.946 102.168 8.166
201909 6.782 102.268 7.965
201912 6.880 102.068 8.096
202003 6.699 102.367 7.860
202006 6.677 101.769 7.880
202009 6.815 101.072 8.099
202012 6.704 101.072 7.967
202103 6.562 102.367 7.699
202106 6.807 103.364 7.910
202109 6.780 104.859 7.766
202112 6.870 106.653 7.737
202203 6.589 109.245 7.244
202206 6.590 112.734 7.021
202209 6.347 113.431 6.721
202212 6.350 115.425 6.608
202303 6.056 117.618 6.184
202306 7.690 119.611 7.722
202309 8.131 120.708 8.091
202312 7.203 120.110 7.203

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alkermes  (NAS:ALKS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alkermes Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alkermes's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451